Chugai Pharmaceutical Co Ltd 2023 AR2
The report details Chugai Pharmaceutical's financial and non-financial performance for the fiscal year 2023, highlighting its progress under the TOP I 2030 growth strategy. Key achievements include the full operation of the Chugai Life Science Park Yokohama and the establishment of the Chugai Venture Fund in Boston to accelerate open innovation. The company reported a Core operating profit of ¥450.7 billion and achieved a 100% sustainable electricity ratio across its domestic business sites. Additionally, Chugai advanced its mid-size molecule drug discovery platform and next-generation antibody technologies, aiming to double its R&D output.
Company: Chugai Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: AR2
Pages: 50
Chugai Pharmaceutical Co Ltd
Annual Report
The report details Chugai Pharmaceutical's financial and non-financial performance for the fiscal year 2023, highlighting its progress under the TOP I 2030 growth strategy. Key achievements include the full operation of the Chugai Life Science Park Yokohama and the establishment of the Chugai Venture Fund in Boston to accelerate open innovation. The company reported a Core operating profit of ¥450.7 billion and achieved a 100% sustainable electricity ratio across its domestic business sites. Additionally, Chugai advanced its mid-size molecule drug discovery platform and next-generation antibody technologies, aiming to double its R&D output.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women in Management
Net Zero Target
Employees